Ropes & Gray represented leading radiopharmaceutical company Lantheus Holdings (NASDAQ: LNTH) in a take-private merger agreement with a wholly-owned subsidiary of Curium US in a transaction valued up to $8 billion. The deal was announced on August 3.
Under the agreement, Curium US will acquire all the outstanding shares of Lantheus for $102.50 per share in cash at closing, plus non-transferable Contingent Value Rights (CVRs) providing for up to $12 per share in potential additional cash payments if certain commercial milestones are met by 2030. Together Lantheus and Curium are positioned to create a radiopharmaceutical company spanning cancer diagnostics and therapeutics with infrastructure to serve patients in more than 70 countries. The Board of Directors of Lantheus has unanimously approved the transaction.
The Ropes & Gray team was led by antitrust partners Mike McFalls, Zak Goodwin and Lisa Kaltenbrunner and included international risk partner Brendan Hanifin and counsel Kurt Fowler and antitrust associate Vincenzo Volpe.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.